BioSante Pharma (BPAX) Tops Q3 EPS by 2c; Bio-T-Gel Gets New PDUFA Date
Tweet
Share
E-mailGet Alerts BPAX Hot Sheet
Join SI Premium – FREE
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) reported Q3 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $182,780 versus the consensus estimate of $30,000.
Announced its Bio-T-Gel was assigned a new PDUFA date of Feb. 14th, 2012.
Announced its Bio-T-Gel was assigned a new PDUFA date of Feb. 14th, 2012.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
- Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
Create E-mail Alert Related Categories
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
